What is FidoCure?
FidoCure operates at the intersection of biotechnology and veterinary medicine, providing a pioneering service that transforms canine cancer treatment through personalized medicine. By utilizing advanced genomic testing, the company tailors therapeutic interventions to the unique genetic profiles of individual dogs, moving beyond the limitations of traditional chemotherapy and radiation. The firm has successfully aggregated the world's largest proprietary cancer data set for canines, positioning itself as an essential partner for veterinarians and pet parents seeking improved prognoses. This data-driven approach not only enhances clinical outcomes but also establishes a new standard for precision medicine in the veterinary sector.
How much funding has FidoCure raised?
FidoCure has raised a total of $10M across 1 funding round:
Other Financing Round
$10M
Other Financing Round (2020): $10M with participation from Tau Ventures, Polaris Partners, Andreessen Horowitz, Y-Combinator, Lerer Hippeau, and Borealis Ventures
Key Investors in FidoCure
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing deep operational expertise to foster innovation.
Lerer Hippeau
Lerer Hippeau is a venture capital firm focused on investing in innovative startups, supporting founders who tackle challenging problems across both enterprise and consumer landscapes.
Borealis Ventures
Borealis Ventures focuses on building visionary healthcare companies by bringing together essential elements for success and supporting innovative solutions in the medical field.
What's next for FidoCure?
With this major enterprise-level funding, FidoCure is well-positioned to accelerate its research and development initiatives. The company is expected to leverage this capital to expand its genomic database, further refining its diagnostic algorithms and therapeutic recommendations. Strategic priorities likely include scaling its operational footprint to reach a broader network of veterinary clinics and deepening its collaborative efforts with research institutions. As the firm transitions into its next phase of growth, the focus will remain on bridging the gap between complex scientific innovation and accessible, life-saving care for pets, ultimately cementing its leadership in the rapidly evolving pet health technology landscape.
See full FidoCure company page
